CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
CRISPR Therapeutics (CRSP) PT Lowered to $59 at Barclays
August 6, 2024 3:02 AM EDTBarclays analyst Gena Wang lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $59.00 (from $67.00) while maintaining a Equalweight rating.... More
CRISPR Therapeutics (CRSP) Misses Q2 EPS by 6c
August 5, 2024 4:04 PM EDTCRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($1.49), $0.06 worse than the analyst estimate of ($1.43).
For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.
... MoreRodman & Renshaw Starts CRISPR Therapeutics (CRSP) at Buy
August 2, 2024 6:44 AM EDTRodman & Renshaw analyst Tony Butler initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Buy rating and a price target of $90.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $54.85 yesterday.
... More